Consolidation and integration of payers/PBMs and of oncology providers means greater standardization of care, more providers at-risk for costs, and better coordination of care.

The increasing cost-shift to insured patients, however, will continue to put pressure on stakeholders to prescribe lower-cost therapies or provide assistance to mitigate cost.

The infographic below offers a high-level view into these trends by looking at:

  • Recent and emerging challenges
  • Shifts toward vertical integration
  • Move towards hospital ownership of oncology practices.

For a deeper dive into these trends, we invite you to stream a recent briefing on these trends by one of our market access specialists. This presentation will take you through recent case studies and offer more context around the implications for pharma.

Stream Now

Click here for downloadable PDF


Market Access Disease Navigator | Oncology

Market Access Disease Navigator enables oncology managed markets teams to see the disease-specific dynamics influencing patient access so you know where to focus tactical planning to make the biggest impact with your contracting, reimbursement, account, marketing, and sales resources.

Learn More

How the pandemic has impacted the Federal Health Insurance Exchange in the U.S.

View Now